{
    "organizations": [],
    "uuid": "99ae31be59705ea84c6266ecfc2ac31510988752",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vbi-vaccines-announces-positive-fi/brief-vbi-vaccines-announces-positive-final-phase-1-study-results-of-preventative-cmv-vaccine-idUSFWN1SH0RB",
    "ord_in_thread": 0,
    "title": "BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10, 2018 / 11:33 AM / in 7 minutes BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine Reuters Staff\nMay 10 (Reuters) - VBI Vaccines Inc:\n* VBI VACCINES ANNOUNCES POSITIVE FINAL PHASE 1 STUDY RESULTS OF PREVENTATIVE CMV VACCINE\n* VBI VACCINES INC - SAFE AND WELL-TOLERATED AT ALL DOSES WITH NO SAFETY SIGNALS OBSERVED IN STUDY\n* VBI VACCINES INC - CMV NEUTRALIZING ANTIBODIES AGAINST FIBROBLAST CELL INFECTION INDUCED IN 100% OF SUBJECTS WHO RECEIVED HIGHEST DOSE IN STUDY Source text for Eikon: Further company coverage:",
    "published": "2018-05-10T14:31:00.000+03:00",
    "crawled": "2018-05-10T14:45:52.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "minute",
        "vaccine",
        "announces",
        "positive",
        "final",
        "phase",
        "study",
        "result",
        "preventative",
        "cmv",
        "vaccine",
        "reuters",
        "staff",
        "may",
        "reuters",
        "vbi",
        "vaccine",
        "inc",
        "vbi",
        "vaccine",
        "announces",
        "positive",
        "final",
        "phase",
        "study",
        "result",
        "preventative",
        "cmv",
        "vaccine",
        "vbi",
        "vaccine",
        "inc",
        "safe",
        "dos",
        "safety",
        "signal",
        "observed",
        "study",
        "vbi",
        "vaccine",
        "inc",
        "cmv",
        "neutralizing",
        "antibody",
        "fibroblast",
        "cell",
        "infection",
        "induced",
        "subject",
        "received",
        "highest",
        "dose",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}